Language
English
Publication Date
7-30-2025
Journal
Cancers
DOI
10.3390/cancers17152520
PMID
40805216
PMCID
PMC12346868
PubMedCentral® Posted Date
7-30-2025
PubMedCentral® Full Text Version
Post-print
Abstract
The American Cancer Society estimates that over 152,000 new cases of colorectal cancer (CRC) were diagnosed in 2024, with more than 105,000 cases affecting the colon and 46,000 involving the rectum. CRC remains the second leading cause of cancer-related deaths in the United States, with an estimated 53,010 deaths in 2024. In the era of precision medicine, which incorporates molecular and environmental information into clinical decision-making, identifying patients harboring a deficiency in Deoxyribonucleic acid (DNA) repair allowed for targeted immunotherapies and significantly reduced CRC-related mortality. A significant advancement in this domain is the application of liquid biopsy, which has emerged as a promising tool for prognostication, guiding therapy, and monitoring treatment response in CRC. This review aims to comprehensively explore the role of liquid biopsy in colorectal malignancies, describing its practical applications, prognostic significance, and potential to revolutionize CRC management in the future. At the end, we also aim to show a schematic representation of showing integration of Circulating Tumor (Ct) DNA in routine clinical management of CRC. The highlight of this article is the structured and evidence-based schematic framework and its integration into future practice. The schematic pathway is designed to optimize ctDNA utilization across various stages of colorectal cancer management.
Keywords
ctDNA, colorectal cancer, prognosis, surveillance
Published Open-Access
yes
Recommended Citation
Vojjala, Nikhil; Gibatova, Viktoriya; Shah, Raj N; et al., "Integrating Circulating Tumor DNA into Clinical Management of Colorectal Cancer: Practical Implications and Therapeutic Challenges" (2025). Faculty and Staff Publications. 4638.
https://digitalcommons.library.tmc.edu/baylor_docs/4638